Home Cart Sign in  
Chemical Structure| 82009-34-5 Chemical Structure| 82009-34-5
Chemical Structure| 82009-34-5

*Storage: Keep in dark place,Sealed in dry,Store in freezer, under -20°C.

Cilastatin

CAS No.: 82009-34-5

Cilastatin is a reversible competitive inhibitor of renal dehydropeptidase I with an IC50 of 0.1 μM, commonly used in antimicrobial therapy, and inhibits bacterial metallo-β-lactamase CphA with an IC50 of 178 μM.

Synonyms: MK0791

4.5 *For Research Use Only !

Cat. No.: A371776 Purity: 95%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
250mg łďÿ¶ÊÊ Inquiry Inquiry Login
1g łÇóò¶ÊÊ Inquiry Inquiry Login
5g łÿÍó¶ÊÊ Inquiry Inquiry Login
10g łîÊÿ¶ÊÊ Inquiry Inquiry Login
25g łÇďÿ˶ÊÊ Inquiry Inquiry Login

Please Login or Create an Account to: See VIP prices and availability

  • 250mg

    łďÿ¶ÊÊ

  • 1g

    łÇóò¶ÊÊ

  • 5g

    łÿÍó¶ÊÊ

  • 10g

    łîÊÿ¶ÊÊ

  • 25g

    łÇďÿ˶ÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations

Martinez-Erro, Samuel ; Navas, Francisco ; Romani-Cubells, Eva , et al.

Abstract: Mesoporous silica nanomaterials have emerged as promising vehicles in controlled drug delivery systems due to their ability to selectively transport, protect, and release pharmaceuticals in a controlled and sustained manner. One drawback of these drug delivery systems is their preparation procedure that usually requires several steps including the removal of the structure-directing agent (surfactant) and the later loading of the drug into the porous structure. Herein, we describe the preparation of mesoporous silica nanoparticles, as drug delivery systems from structure-directing agents based on the kidney-protector drug cilastatin in a simple, fast, and one-step process. The concept of drug-structure-directing agent (DSDA) allows the use of lipidic derivatives of cilastatin to direct the successful formation of mesoporous silica nanoparticles (MSNs). The inherent pharmacol. activity of the surfactant DSDA cilastatin-based template permits that the MSNs can be directly employed as drug delivery nanocarriers, without the need of extra steps. MSNs thus synthesized have shown good sphericity and remarkable textural properties. The size of the nanoparticles can be adjusted by simply selecting the stirring speed, time, and aging temperature during the synthesis procedure. Moreover, the release experiments performed on these materials afforded a slow and sustained drug release over several days, which illustrates the MSNs potential utility as drug delivery system for the cilastatin cargo kidney protector. While most nanotechnol. strategies focused on combating the different illnesses this methodol. emphasizes on reducing the kidney toxicity associated to cancer chemotherapy.

Keywords: cilastatin ; drug delivery systems ; drug-structure-directing agent (DSDA) ; mesoporous silica nanoparticles (MSNs) ; sustained and controlled release

Purchased from AmBeed:

Product Details of [ Cilastatin ]

CAS No. :82009-34-5
Formula : C16H26N2O5S
M.W : 358.45
SMILES Code : O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC[C@H](N)C(O)=O
Synonyms :
MK0791
MDL No. :MFCD00867379

Safety of [ Cilastatin ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.79mL

0.56mL

0.28mL

13.95mL

2.79mL

1.39mL

27.90mL

5.58mL

2.79mL

References

 

Historical Records

Categories